The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

@inproceedings{Kawalec2016TheCB,
  title={The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe},
  author={Paweł Kawalec and Allison Sagan and Andrzej Pilc},
  booktitle={Orphanet journal of rare diseases},
  year={2016}
}
BACKGROUND The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncology) orphan drugs. RESULTS We reviewed drugs authorized by the European Medicine Agency (EMA… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

2007 [accessed 2013 May 10th

  • SMC. Orphan Drug
  • Available from: http://www. scottishmedicines.org…
  • 2016

The use of Comparative Effectiveness Research and Health Technology Assessment in European countries: current situation and prospects for the future

  • D. Epstein
  • Department of Applied Economics, University of…
  • 2014

HTA of orphan drugs across six countries : fair , flawed or failing ?

  • S Aardweg
  • Euro Observer
  • 2010

Similar Papers

Loading similar papers…